FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC By Ogkologos - November 27, 2025 331 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device to aid in detecting HER2 tyrosine kinase domain activating mutations Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Company Gives Cancer Patient a New HVAC System After Treatment and... March 8, 2019 Opinion: ‘Beating cancer means beating it for everyone’ January 29, 2021 No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with... March 3, 2026 2022 ASCO Annual Meeting: A New Targeted Therapy Combination for Low-Grade Brain... June 6, 2022 Load more HOT NEWS Dad Sings “Ave Maria” For His Daughter At Disney World Population-based lung cancer screening can reduce mortality in people who have... FDA Approves Belumosudil for Chronic Graft-Versus-Host Disease Hero Nanny Permanently Injured While Saving 2-Year-Old From Speeding Car About...
